Key points from article :
Subsense, a brain-computer interface (BCI) company, has emerged from stealth mode with $17 million in seed funding led by Golden Falcon Capital. The Covina, California-based company is developing a non-surgical, nanoparticle-based BCI in collaboration with UC Santa Cruz and ETH Zurich. Their goal is to create a safe and accessible system that enhances human interaction with technology.
Unlike traditional BCIs that often require invasive procedures, Subsense’s approach uses biocompatible nanoparticles that bind to brain receptors, enabling seamless connectivity. The company is targeting individuals with paralysis and neurological disorders, aiming to restore motor functions, improve rehabilitation, and even allow users to control devices like smartphones through thought alone.
Beyond movement-related applications, Subsense’s BCI could aid in diagnosing and treating conditions such as Parkinson’s, Alzheimer’s, epilepsy, and chronic pain. Its real-time brain monitoring capabilities may help with early detection of neurological diseases, leading to more precise treatment plans. The company is also exploring potential applications in vision and hearing restoration, inner speech decoding, and even mental health regulation through AI integration.
